News

Bio-G and IMS announced a new toolset for the Life Sciences industry called CrossLink. Effective strategic portfolio management and manufacturing planning requires a comprehensive forecasting system and process. Leading companies need systems that provide real-time visibility into their portfolio, enable quick comparisons and what-if analyses, promote consistency, and drive best practice forecastin

Bio-G has presented data showing key risks to the biomanufacturing process at the 2013 BioInnovations Conference in London, England. In a keynote talk titled: "Risk Time vs. Real Time: Responding to Variability in Biomanufacturing", Bio-G outlined the key risks associated with decision making based on old or inaccurate data. Three case studies were presented looking at real-time statistical process

Join us for this month's webinar, where we discuss a partnership between IMS Consulting Group and Bioproduction Group to build a new, innovative method for portfolio planning in the Life Sciences industry.

The 5th annual Biomanufacturing Summit 2013 attracts senior and executive level industry professionals working within manufacturing, process development and product operations. Bio-G is delivering a talk at this year

Many biomanufacturing facilities are currently designed to run one or a small number of products. However as more (and higher titer) products are approved these facilities are being required to run multiple products at an increased run-rate. Additionally while such facilities may not be ideally suited to it, they are also processing an increasing number of late stage clinical campaigns. This paradi

Clinical / Pilot biomanufacturing facilities are difficult to effectively schedule for two reasons. First, each campaign is different and may involve different resources or fermentors - unlike a commercial facility, where each batch is identical. Second, clinical facilities are required respond to frequent

In this webinar, we examine the impact of variability in biopharmaceutical manufacturing. Using real data, we suggest that variability is the single biggest issue facing biopharmaceutical manufacturers today, affecting not only unit operations but the entire supply chain design and management. The presence of significant variability requires syst

Come by and see us this year at Bioprocess International! This year the conference will be held in Providence, Rhode Island. We'll have a booth and will be demonstrating the new versions of our latest software to perform data analysis, modeling, scheduling and process optimization.

This month, Bio-G will be presenting one of the keynote addresses at the 11th Annual Biological Production Forum, held in Dusseldorf, Germany. The talk, entitled 'Managing the 800 Pound Gorilla in our biomanufacturing facilities' will survey how QbD and other initiatives help manage variability and its impact, how data-driven planning can be used

This webinar focuses on key results from the 9th annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. The report surveys 302 individuals at biotherapeutic developers and CMOs in 29 countries worldwide, plus 186 industry vendors to determine key industry trends. The report is unquestionably the most comprehensive in the industry and shows year-by-year snapshots of cha

In this joint Emerson / Bio-G webinar, we examine the mining of electronic data from Emerson's Syncade™Suite Operations Management software, visualizing and analyzing it in real-time. We'll show how the B

As organizations have started to come to terms with the big data sets they have been collecting, they have started to look for strategies and tools to help them make decisions about what products to make and how to make them most efficiently.

Bio-G's new webinar, "High Titers in Biopharmaceutical Manufacturing" examines a number of approaches to understanding and managing increased titers in commercial biopharmaceutical production. We explore the impact of titer on downstream chromatography steps, buffer preparation

In this 60 minute webinar and Q & A session, our two panelists, Professor Phil Kaminsky from the University of California at Berkeley and Rick Johnston, Ph.D. from Bio-G will present their perspectives on supply chain risks and supply chain risk mitigation in our industry.

Bio-G's new whitepaper, "Capacity Planning in Biomanufacturing" examines the key metrics involved in capacity decisions for biopharmaceutical operations. We demonstrate how to model demand as well as existing and new supply capacity in the 1-10 year planning horizon. Using simple models of risk and variability, we demonstrate how integrated ‘supply-demand’ models can be used to accurately predict a

SAP is used extensively in the biomanufacturing industry, and now this important, real-time data can be integrated with other data sources, visualized and analyzed using the Bio-G real-time modeling system. Because the Bio-G real-time modeling system is "aware" of all the steps in the manufacturing process, variability, resources and their complex interdependencies,

Capacity planning for new molecules in biotech is fraught with uncertainty. Supply constraints, unknown titers, number of patients and dosing as well as probability of technical success (PTS), make capacity planning difficult. And while building insufficient capaci

About us

Welcome! We are experts in biomanufacturing and we understand the challenges you face: coping with the complexity of biotechnology and the manufacturing process, the avalanche of supply chain and production data, the consolidation of facilities, the cost of inefficiencies and bottlenecks, and maximizing production throughput while maintaining quality.